Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
- PMID: 37225997
- PMCID: PMC10208202
- DOI: 10.1038/s41586-023-05977-x
Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
Erratum for
- doi: 10.1038/s41586-021-03791-x
Similar articles
-
Time and cost of administering COVID-19 mRNA vaccines in the United States.Hum Vaccin Immunother. 2021 Nov 2;17(11):3871-3875. doi: 10.1080/21645515.2021.1974289. Epub 2021 Oct 6. Hum Vaccin Immunother. 2021. PMID: 34613860 Free PMC article.
-
Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine.J Infect. 2022 Jan;84(1):94-118. doi: 10.1016/j.jinf.2021.08.008. Epub 2021 Aug 8. J Infect. 2022. PMID: 34371075 Free PMC article. No abstract available.
-
What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?EBioMedicine. 2021 Dec;74:103733. doi: 10.1016/j.ebiom.2021.103733. Epub 2021 Dec 1. EBioMedicine. 2021. PMID: 34864362 Free PMC article. No abstract available.
-
Advances of Reverse Vaccinology for mRNA Vaccine Design against SARS-CoV-2: A Review of Methods and Tools.Viruses. 2023 Oct 21;15(10):2130. doi: 10.3390/v15102130. Viruses. 2023. PMID: 37896907 Free PMC article. Review.
-
mRNA Vaccine - A New Cancer Treatment Strategy.Curr Cancer Drug Targets. 2023;23(9):669-681. doi: 10.2174/1568009623666230222124424. Curr Cancer Drug Targets. 2023. PMID: 36809966 Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources